These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10603734)

  • 1. [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].
    Ambrosch A; König W
    Med Klin (Munich); 1999 Nov; 94(11):626-32. PubMed ID: 10603734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and evolving therapies for hepatitis C.
    Moradpour D; Blum HE
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis, diagnosis and management of hepatitis C.
    Boyer N; Marcellin P
    J Hepatol; 2000; 32(1 Suppl):98-112. PubMed ID: 10728798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
    Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
    J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis for responsiveness to anti-viral therapy in hepatitis C.
    Polyak SJ; Gerotto M
    Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent trends in the therapy of hepatitis C].
    Meschini A; Lucchetta MC; Fontana M; Nocchi S; Pace A; Grassi M
    Clin Ter; 2003; 154(3):181-91. PubMed ID: 12910808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
    El Sayed ZM; Mansour FA; Ghal MF; Abou-Zahra SB
    Immunol Invest; 2011; 40(1):29-38. PubMed ID: 20809700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.
    Nasu A; Marusawa H; Ueda Y; Nishijima N; Takahashi K; Osaki Y; Yamashita Y; Inokuma T; Tamada T; Fujiwara T; Sato F; Shimizu K; Chiba T
    PLoS One; 2011; 6(9):e24907. PubMed ID: 21966381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
    Grahovac B; Bingulac-Popovic J; Vucelic B; Hrstic I; Ostojic R; Drazic V; Balija M; Grgicevic D
    J Clin Virol; 2001 Jan; 20(1-2):85-9. PubMed ID: 11163588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hepatitis C.
    Teo M; Hayes P
    Br Med Bull; 2004; 70():51-69. PubMed ID: 15466491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
    Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
    Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection.
    Fernández I; Castellano G; Domingo MJ; Fuertes A; Colina F; Canga F; de la Cruz FJ; de la Cámara AG; Solís JA
    Scand J Gastroenterol; 1997 Jan; 32(1):70-6. PubMed ID: 9018770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.